Results 91 to 100 of about 20,619 (221)

Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database. [PDF]

open access: yes, 2017
Acromegaly is a rare disorder caused by chronic growth hormone (GH) hypersecretion. While diagnostic and therapeutic methods have advanced, little information exists on trends in acromegaly characteristics over time.
Sievers C   +25 more
core   +2 more sources

Patients With Pituitary Neuroendocrine Tumours Requiring Neurosurgery –Who Is Referring Them?

open access: yesClinical Endocrinology, Volume 104, Issue 4, Page 352-361, April 2026.
ABSTRACT Objective Patients living with pituitary neuroendocrine tumours (PitNETs) present with a spectrum of clinical manifestations and often follow a circuitous route to diagnosis, resulting in diagnostic delays. The objective of this study is to identify and report the various sources of referrals for patients who underwent pituitary resection for ...
Doua S. Ahmed   +11 more
wiley   +1 more source

European Society of Neuroendocrine Tumors (ENETS) 2025 guidance paper for lung and thymic carcinoids

open access: yesJournal of Neuroendocrinology, Volume 38, Issue 4, April 2026.
Abstract This ENETS guidance paper, developed by a multidisciplinary working group, provides up‐to‐date and practical advice on the diagnosis and management of lung and thymic carcinoids, based on recent developments and study results. These recommendations aim to provide practical recommendations for the diagnosis, treatment and follow‐up of these ...
Eric Baudin   +12 more
wiley   +1 more source

Sclerostin levels in patients with acromegaly

open access: yesEndokrynologia Polska
Acromegaly is a rare, endocrine condition characterized by autonomous excessive secretion of growth hormone, causing numerous complications, including impairment of bone microarchitecture.
Arnika Wydra   +4 more
doaj   +1 more source

BACKGROUND CHANGES OF THE DIGESTIVE SYSTEM MUCOSA IN PATIENTS WITH ACROMEGALY

open access: yesAlʹmanah Kliničeskoj Mediciny, 2016
Background: Gastrointestinal tract lesions due to the growth hormone impact on mucosa of both the stomach and colon contribute to the complications of acromegaly.
A. A. Titaeva   +4 more
doaj   +1 more source

Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.

open access: yes, 2010
CONTEXT: Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with affinity for somatostatin receptor subtypes sst(1-3) and sst(5).
Schopohl J.   +12 more
core  

Leptin Level in Newly Diagnosed Iraqi Acromegaly Patients

open access: yesAl-Mustansiriyah Journal of Pharmaceutical Sciences, 2018
Acromegaly is a serious endocrine disease resulting from an increase of growth hormone in the blood. Excessive growth hormone secretion may be caused by an adenoma of the pituitary.
Noor Thair Tahir
doaj   +1 more source

Patient perspectives on the impact of acromegaly: results from individual and group interviews

open access: yes, 2014
Michelle H Gurel,1 Paul R Bruening,2 Christine Rhodes,2 Kathleen G Lomax31Neuroendocrine Clinical Center, Massachusetts General Hospital, Boston, MA, USA; 2Nicholas Research Associates International, New York, NY, USA; 3Medical Affairs, Ipsen ...
Lomax KG   +3 more
core  

Análise dos casos de agromegalia do Hospital Governador Celso Ramos [PDF]

open access: yes, 2011
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Lacerda, Afonso Henrique Bevilacquia Baleeiro
core  

Acromegaly

open access: yes, 2011
Acromegaly is the condition most often associated with an anterior pituitary tumour, which results from growth hormone and insulin-like growth factor 1 (IGF-1) excess.
John A. H. Wass   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy